תלידומיד בי אם אס 50 מג כמוסות קשיחות İsrail - İbranice - Ministry of Health

תלידומיד בי אם אס 50 מג כמוסות קשיחות

neopharm ltd - thalidomide - קפסולה קשיחה - thalidomide 50 mg - thalidomide

תלידומיד סלג'ן 50 מג כמוסות קשיחות İsrail - İbranice - Ministry of Health

תלידומיד סלג'ן 50 מג כמוסות קשיחות

neopharm ltd - thalidomide - קפסולה קשיחה - thalidomide 50 mg - thalidomide

לקוסמיד טבע  50 מג   İsrail - İbranice - Ministry of Health

לקוסמיד טבע 50 מג

abic marketing ltd, israel - lacosamide - טבליות מצופות פילם - lacosamide 50 mg - lacosamide

אונג'נטיס 50 מג İsrail - İbranice - Ministry of Health

אונג'נטיס 50 מג

truemed ltd, israel - opicapone - קפסולה קשיחה - opicapone 50 mg - opicapone

ג'נואט 50 מג500 מג İsrail - İbranice - Ministry of Health

ג'נואט 50 מג500 מג

merck sharp & dohme (israel - 1996) company ltd, israel - metformin hydrochloride; sitagliptin as monohydrate phosphate - טבליה - sitagliptin as monohydrate phosphate 50 mg; metformin hydrochloride 500 mg - metformin - metformin - januet is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus. important limitations of use:januet should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.januet has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using januet.

ג'נואט 50 מג850 מג İsrail - İbranice - Ministry of Health

ג'נואט 50 מג850 מג

merck sharp & dohme (israel - 1996) company ltd, israel - metformin hydrochloride; sitagliptin as monohydrate phosphate - טבליה - sitagliptin as monohydrate phosphate 50 mg; metformin hydrochloride 850 mg - metformin - metformin - januet is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus. important limitations of use:januet should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.januet has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using januet.

לוסרדקס 50 İsrail - İbranice - Ministry of Health

לוסרדקס 50

dexcel pharma technologies ltd - losartan potassium - טבליה - losartan potassium 50 mg - losartan - losartan - hypertension: losardex is indicated for the treatment of hypertension. heart failure: losardex is indicated for the treatment of heart failure (nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to losardex is not recommended. renal protection in type-2 diabetic patients with proteinuria: losardex is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease (need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. losardex is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventric

לוסרדקס 50 İsrail - İbranice - Ministry of Health

לוסרדקס 50

dexcel pharma technologies ltd - losartan potassium - טבליה - losartan potassium 50 mg - losartan - losartan - hypertension: losardex is indicated for the treatment of hypertension. heart failure: losardex is indicated for the treatment of heart failure (nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to losardex is not recommended. renal protection in type-2 diabetic patients with proteinuria: losardex is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease (need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. losardex is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventric

ויאגרה 50 מג İsrail - İbranice - Ministry of Health

ויאגרה 50 מג

pfizer pfe pharmaceuticals israel ltd - sildenafil as citrate - טבליות מצופות פילם - sildenafil as citrate 50 mg - sildenafil - sildenafil - treatment of erectile dysfunction.

יוטירוקס 50 מקג İsrail - İbranice - Ministry of Health

יוטירוקס 50 מקג

merck serono ltd - levothyroxine sodium - טבליה - levothyroxine sodium 50 mcg - levothyroxine sodium - levothyroxine sodium - euthyrox 25 - 200 microgram :- treatment of benign euthyroid goitre.- prophylaxis of relapse after surgery for euthyroid goitre, depending on the post - operative hormone status.- substitution therapy in hypothyroidism.- suppression therapy in thyroid cancer.euthyrox 25 - 100 microgram :- concomitant supplementation during anti-thyroid drug treatment of hyperthyroidism.euthyrox 100/150/200 microgram :- diagnostic use for thyroid suppression testing.